IP Library › Granted Patent US 12,209,131
Granted Patent B2
US 12,209,131 · App. 17/267,157 · Granted Jan 28, 2025

Anti-IL1RAP antibody compositions

Inventors: Göran Forsberg (Eslöv, SE); David Liberg (Lomma, SE); Kjell Sjöström (Lund, SE); Karin von Wachenfeldt (Lund, SE)
Assignee: Cantargia AB
C07K16/2866A61P35/00C07K16/244C07K2317/21C07K2317/24C07K2317/33C07K2317/526C07K2317/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,209,131
App. No.
17/267,157
Granted
Jan 28, 2025
Kind
B2
Abstract

The present invention relates to antibody compositions directed to Interleukin 1 Receptor Accessory Protein (IL1RAP) and their use in the treatment and diagnosis of diseases associated with IL1RAP, such as inflammatory, autoimmune, autoinflammatory and neoplastic disorders.

Claims (62)

1. A bi-epitopic binding agent comprising:

a first antigen-binding region, and

a second antigen-binding region,

wherein the first antigen binding region and the second antigen binding region bind to different extracellular domains of human interleukin-receptor accessory protein (IL1RAP), and wherein

a) the first antigen-binding region is comprised of the following six complementary determining regions (CDRs):

Light chain CDR1:

(SEQ ID NO: 29)

ASQGINNYLN;

Light chain CDR2:  

(SEQ ID NO: 9)

YTSGLHAGV or 

(SEQ ID NO: 22)

YTSGLHA;

Light chain CDR3:  

(SEQ ID NO: 10) 

QQYSILPWT or

(SEQ ID NO: 23)

QYSILPWT;

Heavy chain CDR1: 

(SEQ ID NO: 24)

GYAFTSS;

Heavy chain CDR2: 

(SEQ ID NO: 12)

RIYPGDGNTHYAQKFQG or 

(SEQ ID NO: 25)

YPGDGN;

Heavy chain CDR3: 

(SEQ ID NO: 13)

GYLDPMDY;

and

b) the second antigen-binding region is comprised of the following six complementary determining regions (CDRs):

Light chain CDR1: 

(SEQ ID NO: 16)

RASQSIGTSIH or 

(SEQ ID NO: 30)

ASQSIGTSIH;

Light chain CDR2: 

(SEQ ID NO: 17)

SASESIS;

Light chain CDR3: 

(SEQ ID NO: 18) 

QQSNSWPTT or 

(SEQ ID NO: 26)

QSNSWPTT;

Heavy chain CDR1: 

(SEQ ID NO: 19)

GFTFSIYTMS or 

(SEQ ID NO: 27)

GFTFSIY;

Heavy chain CDR2: 

(SEQ ID NO: 20)

TISIGGSYINYPDSVKG or 

(SEQ ID NO: 28)

SIGGSY;

Heavy chain CDR3: 

(SEQ ID NO: 21)

EVDGSYAMDY,

wherein the first antigen-binding region comprises an amino acid sequence comprising or consisting of the heavy chain amino acid sequence SEQ ID NO: 35 and the light chain amino acid sequence SEQ ID NO: 36, and wherein the second antigen-binding region comprises the heavy chain amino acid sequence SEQ ID NO: 37 and the light chain amino acid sequence SEQ ID NO: 38.

2. The bi-epitopic binding agent according to claim 1 , wherein the bi-epitopic binding agent is a dual-variable-domain antibody, a bivalent bispecific antibody, a monovalent bispecific antibody, a ‘knob-in-hole’ bispecific antibody, a scFv2_Fc bispecific antibody, a DVD-Ig bispecific antibody, an IgG-Fab bispecific antibody, a FAb-IgG bispecific antibody, a DART-based bispecific antibody, or a DNL-Fab3 bispecific antibody.

3. An isolated polynucleotide encoding the bi-epitopic binding agent according to claim 1 .

4. A host cell comprising (a) one or more polynucleotides which, collectively or individually, encode the bi-epitopic binding agent according to claim 1 ; or (b) one or more expression vectors comprising the one or more of the polynucleotides in (a).

5. A pharmaceutical composition comprising the bi-epitopic binding agent according to claim 1 and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2021
From: FORSBERG, GÖRAN; LIBERG, DAVID; SJÖSTRÖM, KJELL; VON WACHENFELDT, KARIN
To: CANTARGIA AB
Reel/Frame 055198/0413 →
Priority Claims (1)
SE 1850983-6 · Aug 16, 2018 · national
Continuity (1)
Related Publication 20220267454A1 · Aug 25, 2022
References Cited (98)
US 5225539A · Winter · 1993 [cited by applicant]
US 6180370B1 · Queen et al. · 2001 [cited by applicant]
US 9403906B2 · Fioretos et al. · 2016 [cited by applicant]
US 9458237B2 · Fioretos et al. · 2016 [cited by applicant]
US 9796783B2 · Ågerstam · 2017 [cited by examiner]
US 10005841B2 · Fioretos et al. · 2018 [cited by applicant]
US 10005842B2 · Fioretos et al. · 2018 [cited by applicant]
US 10100119B2 · Ågerstam · 2018 [cited by examiner]
US 10287357B2 · Ågerstam · 2019 [cited by examiner]
US 10562971B2 · Ågerstam · 2020 [cited by examiner]
US 10752692B2 · Ågerstam · 2020 [cited by examiner]
US 10878703B2 · Fioretos et al. · 2020 [cited by applicant]
US 10995144B2 · Fioretos et al. · 2021 [cited by applicant]
US 11236172B2 · Ågerstam · 2022 [cited by examiner]
US 11359025B2 · Jiang et al. · 2022 [cited by applicant]
US 11479610B2 · Liberg et al. · 2022 [cited by applicant]
US 20060228300A1 · Chang et al. · 2006 [cited by applicant]
US 20060228357A1 · Chang et al. · 2006 [cited by applicant]
US 20070086942A1 · Chang et al. · 2007 [cited by applicant]
US 20070140966A1 · Chang et al. · 2007 [cited by applicant]
US 20170121420A1 · Heidrich et al. · 2017 [cited by applicant]
US 20180002430A1 · Ågerstam · 2018 [cited by examiner]
US 20180044425A1 · Ågerstam · 2018 [cited by examiner]
US 20210261674A1 · Fioretos et al. · 2021 [cited by applicant]
US 20220106396A1 · Ågerstam et al. · 2022 [cited by applicant]
US 20220267454A1 · Forsberg et al. · 2022 [cited by applicant]
JP 2010116338A · 2010 [cited by applicant]
WO WO9308829A1 · 1993 [cited by applicant]
WO 9400136A1 · 1994 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO0243478A2 · 2002 [cited by applicant]
WO 2011021014 · 2011 [cited by applicant]
WO WO2013074569A1 · 2013 [cited by applicant]
WO 2015132602 · 2015 [cited by applicant]
WO WO2015132602A1 · 2015 [cited by examiner]
WO WO2016020502A1 · 2016 [cited by examiner]
WO 2017093448A1 · 2017 [cited by applicant]
WO 2018071910 · 2018 [cited by applicant]
WO 2012098407 · 2020 [cited by applicant]
WO 2022136569 · 2022 [cited by applicant]
Spiess et al. Molecular Immunology. 67: 95-106; Published: Jan. 27, 2015 (Year: 2015). [cited by examiner]
Forsberg. IL1RAP as a therapeutic target; PEGS Boston Summit Apr. 30-May 4, 2018 (Year: 2018). [cited by examiner]
Agerstam et al.: “Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia”, PNAS, vol. 112, No. 34, Aug. 25, 2015, pp. 10786-10791, XP055308490, DOI: 10.1073/pnas… [cited by applicant]
Agerstam et al.: “IL1RAP antibodies block IL-1 induced expansion of candidate CML stem cells and mediate cell killing in xenograft models”, Blood, vol. 128, No. 23, Sep. 12, 2016, pp. 2683-2693, XP055494589, Doi: 10.118… [cited by applicant]
Barbas, C. F. et al. “in vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity”, Proc. Natl. Acad. Sci. USA, vol. 91: 3809-13, Ap… [cited by applicant]
Blumberg. H., et al. IL-1RLZ and its Ligands contribute to the cytokine network in Psoriasis, J Immunol 2010, 185: 4354-62. [cited by applicant]
Brennan, M. et al. “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments”, Science, Jul. 5, 1985, 229(4708): 81-3. [cited by applicant]
Dinarello, C. A. “The IL-1 family and inflammatory diseases”, Clin Exp Rheumatol, Sep.-Oct. 2002, vol. 20(5 Suppl 27): S1-13. [cited by applicant]
Dinarello, C.A. “Proinflammatory cytokines”, Chest. Aug. 2000; 118(2): 503-508. [cited by applicant]
Dinarello, C. et al. “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases”, Aug. 2012, Nature Reviews Drug Discov, vol. 11(8), pp. 633-652. [cited by applicant]
Dinarello, Charles A. “An expanding role for interleukin-1 blockade from Gout to cancer”, Dec. 2014, Mol. Med. 20(suppl. 1):S43-S58. [cited by applicant]
Dinarello, Charles A. “Biologic basis for Interleukin-1 in Disease”, Blood Mar. 15, 1996, 87(6): 2095-147). [cited by applicant]
Foster, A.M., et al. “IL-36 promotes myeloid cell infiltration, activation and inflammatory activity in skin”, J Immunol, Jun. 15, 2014, 192(12): 6053-61. [cited by applicant]
Gabay C. and Towne, J. E. “Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions”, J Leukocyte Biol Apr. 2015, vol. 97: 645-52. [cited by applicant]
Greener et al. “In Vitro Mutagenesis Protocols”, Humana press, NJ, 1996. [cited by applicant]
Gruber et al. “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in [cited by applicant]
Gudjonsson, J. et al.: “Mouse Models of Psoriasis”, J Investigative Dermatology (2007) 127: 1292-1308, doi:10.1038/sj.jid.5700807. [cited by applicant]
Günther, S. et al: “Molecular determinants of Agonist and Antagonist Signaling through the IL-36 receptor”, J. Immunol. 2014 193: 921-30. [cited by applicant]
Hawkins, R.E. et al. “Selection of phage antibodies by binding affinity: Mimicking affinity maturation”, J. Mol. Biol. Aug. 5, 1992, vol. 226(3): 889-96. [cited by applicant]
Hollinger, P. et al. “Diabodies: Small bivalent and bispecific antibody fragments”, Proc. Natl. Acad. Sci. USA, vol. 90: 6444-6448, Jul. 1993. [cited by applicant]
Huang, J. et al., “Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein”, Proc. Natl. Acad. Sci. USA, vol. 94, Nov. 25, 1997, pp. 12829-12832. [cited by applicant]
Jackson, J. R. et al. “In vitro antibody maturation. Improvement of a high affinity, neutralizing antibody against IL-1 beta”, J. Immunol. Apr. 1, 1995, 154(7): 3310-19 (1995). [cited by applicant]
Jones, P. T. et al., “Replacing the complementarity-determining regions in a human antibodywith those from a mouse”; Nature, vol. 321, May 29, 1986, 522-525. [cited by applicant]
Järås, M. et al., “Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein”, PNAS, Sep. 14, 2010, vol. 107, No. 37, 16280-16285. [cited by applicant]
Kabat et al.“Sequences of Proteins of Immunological Interest”, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991). [cited by applicant]
Kolkman, J. A. et al. “Directed evolution of proteins by exon shuffling”, Nat Biotechnol. May 2001; 19(5):423 -8. [cited by applicant]
Kontermann, R. et al.: “Bispecific antibodies”, Drug Discovery Today, vol. 20(7) Jul. 2015. [cited by applicant]
Kopsidas, G. et al. “In vitro improvement of a shark IgNAR antibody by QB replicase mutation and ribosome display mimics in vivo affinity maturation”, Immunol Lett. 2006, vol. 107(2) Nov. 15, 2006:163-8. [cited by applicant]
Kostelny, S. A. et al. “Formation of a bispecific antibody by the use of leucine zippers”, J. Immunol., Mar. 1, 1992, vol. 148(5): 1547-1553. [cited by applicant]
Kundu-Raychaudhuri, S. et al.: “Severe combined immunodeficiency mouse-psoriatic human skin xenograft model: A modern tool connecting bench to bedside”, Indian J Dermatology, Venereology, and Leprology vol. 80(3) May-Ju… [cited by applicant]
Labrijn, A. F. et al. “Efficient generation of stable bispecific lgG1 by controlled Fab-arm exchange”, Proc Natl Acad Sci USA, Mar. 26, 2013; vol. 110(13): 5145-5150. [cited by applicant]
Liew, F. Y. et al. “Interleukin-33 in health and disease”, Nat Rev Immunol Sep. 19, 2016, 16:676-89. [cited by applicant]
Lindhofer, H. et al. “Preferential species-restricted heavy-light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies”, J Immunol. Jul. 1995, 155(1): 219-225 (1995). [cited by applicant]
Liu, X. et al.: “Structural insights into the interaction of IL-33 with its receptors”, PNAS Sep. 10, 2013, vol. 110(37): 14918-23. [cited by applicant]
Lonberg, N. et al. “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature 368: 856-859 (1994). [cited by applicant]
Marks, J.D. et al. “By-passing immunization: building high affinity human antibodies by chain shuffling”, Biotechnology, Jul. 1992, 10(7): 779-83. [cited by applicant]
Milstein, C. et al. “Hybrid hybridomas and their use in immunohistochemistry”, Nature, 305: 537-540 (1983). [cited by applicant]
Mutamba, S., et al. “Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9”, Eur J Immunol, Mar. 2012, 42(3): 607-17. [cited by applicant]
Peled, J. U. et al. “The biochemistry of somatic hypermutation”, Annu Rev Immunol. 2008, 26:481-511. [cited by applicant]
Presta, Leonard G.: “Antibody engineering”, Struct. Biol. , vol. 2, Issue 4, Aug. 1992, pp. 593-596. https://doi.org/10.1016/0959-440X(92)90091-K. [cited by applicant]
Queen, C. et al. “A humanized antibody that binds to the interleukin 2 receptor”, PNAS USA, Dec. 1989, vol. 86: 10029-33. [cited by applicant]
Riechmann, L. et al., “Reshaping human antibodies for therapy”, Nature, vol. 332, Mar. 24, 1988, 323-327. [cited by applicant]
Schier, R. et al. “Identification of functional and structural aminoacid residues by parsimonious mutagenesis”, Gene, vol. 169(2): 147-155, 1996. [cited by applicant]
Schmitz, J. et al. “IL-33, an Interleukin-1-like Cytokine that signals via the IL-1 Receptor-related Protein ST2 and induces T helper type 2-associated cytokines”, Immunity Nov. 2005, vol. 23, 479-90. [cited by applicant]
Shalaby, M. R. et al. “Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene”, J. Exp. Med. vol. 175, Jan. 1992: 217-225. [cited by applicant]
Suresh, M. R. et al. “Bispecific monoclonal antibodies from hybrid hybridomas”, Methods Enzymol. 1986, vol. 121: 210-28. [cited by applicant]
Thie, H. et al. “Therapeutic Antibodies”, Methods Mol Biol, vol. 525: 309-322 (2009). [cited by applicant]
Thomas, C et al.: “Structure of the activating IL-1 receptor signaling complex”, Nat Struct Mol Biol 2012 19(4):455-457. [cited by applicant]
Thompson, J. D. et al. “Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice”, Nucleic Acids Res. vol. 22(2… [cited by applicant]
Traunecker et al. “Bispecific single chain molecules (Janusins) target cytotoxic Lymphocytes on HIV infected cells”, Embo J., vol. 10(12): 3655-3659 (1991). [cited by applicant]
Tutt, A. et al. “Trispecific F(ab′ )3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells”, J. Immunol. Jul. 1, 1991, vol. 147(1): 60-69. [cited by applicant]
Verhoeyen, M. et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science, New Series, vol. 239, No. 4847 (Mar. 25, 1988), pp. 1534-1536. [cited by applicant]
Wang et al., “Structural insights into the assembly and activation of IL-1b with its receptors”, nature immunology vol. 11 No. 10 Oct. 2010, 905-912, doi:10.1038/ni.1925. [cited by applicant]
Wu C. et al. “Molecular construction and optimization of anti-human IL-1 a/B dual variable domain immunoglobulin (DVD-lg tm) molecules”, MAbs 1:4 : 339-347, Jul./Aug. 2009. [cited by applicant]
Wu C. et al. “Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin”, Nat. Biotechnol. 25; 1290-1297 (2007). [cited by applicant]
Xu et al. “Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system”, mAbs 7(1): 231-242; Jan./Feb. 2015. [cited by applicant]
Yelton, D.E. et al. “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis”, J. Immunol. Aug. 15, 1995, vol. 55(4): 1994-2004. [cited by applicant]
Yoon, et al. “Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1 B Activity but not Binding: Regulation of IL-1 responses is via type I receptor, not the accessory protein”, J Immunol 1… [cited by applicant]